Article Hero

Pfizer reported revenue below-the-expectations

1603810632.jpg
Miguel A. Rodriguez
Miguel A. Rodriguez
27 Octombrie 2020
Pfizer reported mixed quarterly figures. The company’s waiting for the independent monitor to approve its potential COVID-19 vaccine

After it announced the lengths that will go to in order to have the proper conditions to distribute its potential COVID-19 vaccine, Pfizer made public its Q3 earnings.

The New York-based company reported earnings per share of 0.72 cents on revenue of $12.13 billion. While the EPS came higher than the 0.69 cents expected, the revenue fell short of the $12.31 billion mark.

Along with the Q3 figures came other news. According to Pfizer’s statement, the company’s not ready to go public with the data it collected during the late-stage trials of its potential COVID-19 vaccine that it’s developing alongside Germany’s BioNTech. Pfizer said that the independent monitor hadn’t conducted an in-depth analysis to show whether the drug was efficient.

Since the beginning of the year, the company’s stock price fell 3%, while USA500 gained 4.45%.

Read here more about Pfizer!

Sources: investing.com, reuters.com

disclaimers_articles

article_share_title

article_rating_title

awful
ok
great
awesome

read_more

Miguel A. Rodriguez
Miguel A. Rodriguez
financial_writer

Miguel a lucrat pentru instituții financiare importante, precum Banco Santander și Banco Central-Hispano. De asemenea, a publicat cărți despre Forex.